Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Califf Nomination Adds New Dynamic, Maybe New Provisions, To FDA Reform Bills

Executive Summary

Senate legislation may be influenced by movement to push through Califf’s nomination for FDA commissioner.

You may also be interested in...



Califf Nomination May Show Confidence In His Bipartisan Appeal

After seven months as deputy commissioner for medical products and tobacco, Robert Califf tapped to be FDA Commissioner.

PDUFA Budgeting: What Will Get Added, Subtracted – Or Multiplied By Cures?

Industry official sees potential for some streamlining in user fee program, but adding to breakthrough and patient-centered activities seems most likely.

Senator Tells FDA To Create ‘Red Team’ For Regulatory Streamlining

HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel